You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. TeamChip for High-throughput, Predictive Human Metabolism and Toxicology

    SBC: Solidus Biosciences, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with Rensselaer Polytechnic Institute is proposing to address a critical need in chemical safety technology through its proprietary Transfected Enzyme and Metabolism Chip (or TeamChip) for high-throughput analysis of systematic drug candidate and chemical metabolism and toxicology. The TeamChip is being developed to mi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. VirtualDose Software for Diagnostic CT Doses to Adults and Children

    SBC: VIRTUAL PHANTOMS INC            Topic: NIBIB

    DESCRIPTION (provided by applicant): This project aims to develop a commercial software product, VirtualDoseTM, for calculating and analyzing patient radiation doses from x-ray computed tomography (CT) examinations. Despite its essential role in radiology, CT is responsible for raising the collective medical radiation dose to the American population to a level that is associated with measurable a ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Screens for Novel Agonists/Antagonists of Endocrine Fibroblast Growth Factors

    SBC: AGAVE BIOSYSTEMS INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Agave BioSystems and Professor Makoto Kuro-o at the University of Texas Southwestern Medical Center are proposing a collaborative effort to screen for novel small molecules acting as agonists or antagonists of the Klotho and Klotho- dependent endocrine Fibroblast Growth Factors. The expected outcome of this Phase I effort will be the validation of a high-throug ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: ENGINEERING RESOURCES GROUP INC            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Star-dots fluorescent nanoparticles for flow cytometry and biomedical imaging

    SBC: Nanoscience Solutions, LLC            Topic: NIAID

    Fluorescent nanoparticlesFNPare becoming increasingly popular in biomedical imaging and taggingCompared to molecule based fluorophoresFNP are typically brighter and more photostableThey can be functionalized with more than one tagging moleculeused for the tagging and tracing of specific moleculescellstissuesBrighter fluorescence facilitates more sensitive labelingand in many casesa lower limit of ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin

    SBC: EYERX RESEARCH, INC.            Topic: NEI

    Project Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug concentrations that then create formulation ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO

    SBC: EYERX RESEARCH, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Over the past sixty years, antibiotics have comprised a key component in both the treatment and prophylaxis of bacterial infections. Since that time the continuous development of new antibiotics has been necessary to limit toxicity, promote broader spectrum therapy, increase convenience of use, and decrease the time to clear the infection. Another driving force ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government